Fate Therapeutics, Inc. (FATE) News
Filter FATE News Items
FATE News Results
|Loading, please wait...|
FATE News Highlights
- 500 - Internal server error
- Over the past 13 days, the trend for FATE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest FATE News From Around the Web
Below are the latest news stories about Fate Therapeutics Inc that investors may wish to consider to help them evaluate FATE as an investment opportunity.
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET. The live webcast of the presentation can be accessed under "E
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 5:00 p.m. ET to report its second quarter 2021 financial results and provide a corporate update. In order to participate in the conference call, please dial 800-773-2954 (toll
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Stock markets run on fear and greed in the short term.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Officer. Dr. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical operations, having led teams in the commercial-scale cGMP manufacture and distribution, as well as the clinical-stage process, assay, and formulation development, of complex biologics. As Chief Technical Officer, Mark will oversee the Companys manufacturing, technical, and supply chain operations.
Investors Alley Heres Why FATEs Stock Priced Popped FATEs stock price was higher on Friday because Fate Therapeutics (FATE) highlighted positive interim data from its study of FT516 in combination with Rituximab for B-cell Lymphoma. FT516 is the Companys universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity,  Heres Why FATEs Stock Priced Popped Ian Cooper
BMO Capital Stick to Their Hold Rating for Fate Therapeutics
Oppenheimer Stick to Their Buy Rating for Fate Therapeutics